Dr. Karl Thomae

Dr. Karl Thomae GmbH was a prominent German pharmaceutical company based in Biberach an der Riß, recognized for its significant contributions to respiratory and cardiovascular medicine. Founded in 1946, the company developed several globally successful drugs, including the secretolytic agent Bisolvon and the antiplatelet medication Persantin. It became a major subsidiary of Boehringer Ingelheim shortly after its founding and was eventually fully integrated into the parent company's operations. Today, the former Thomae site serves as Boehringer Ingelheim's largest research and development center and a primary hub for biopharmaceutical production. The company's legacy remains central to the therapeutic advancements in mucus regulation and platelet aggregation inhibition.